Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial
Ludwig Kappos(Novartis (Switzerland)), Christoph Pohl, Hans‐Peter Hartung(The University of Sydney), Frederik Barkhof(Netherlands Institute for Neuroscience), Vivian Lanius(Bayer (Germany)), Rupert Sandbrink(Io Therapeutics (United States)), Gilles Edan(Centre National de la Recherche Scientifique), David H. Miller(National Hospital for Neurology and Neurosurgery), Ernst‐Wilhelm Radü(University Hospital of Basel), Mark S. Freedman, Chris H. Polman(Vrije Universiteit Amsterdam), Carola Metzig(Vall d'Hebron Hospital Universitari), Lars Bauer(UCB Pharma (Germany)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya)
Cited by 370
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
|Annals of Neurology|2001|7k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”
|Annals of Neurology|2005|5k